By: Adam Feuerstein | 05/15/14 - 09:30 AM EDT
The specific case study announced today involves a sarcoma patient with a large tumor mass and multiple inoperable metastatic tumors in the lung. This patient received the first 3 DCVax-Direct injections through the course of a month, starting in February. He received a fourth injection in early April and then was scanned for results in early May. At that time, this patient's MRI scan showed extensive necrosis and partial collapse of the injected large tumor mass, and a CT scan showed some early indication of shrinkage of one of the non-injected metastasized tumors. These results suggest both local and systemic effects of the DCVax-Direct treatment, as were seen in the pre-clinical studies.
Touting "case studies" about cancer drugs is grossly unethical. Pandering to a market of dying patients. The stuff of snake oil sales. $NWBO John Carroll (@JohnCFierce) May 15, 2014
11/19/14 - 01:25 PM EST
11/18/14 - 10:16 AM EST
11/13/14 - 04:34 PM EST
11/10/14 - 10:40 AM EST
11/06/14 - 11:31 AM EST
11/22/14 - 14:07 PM EST
11/21/14 - 10:53 AM EST
11/20/14 - 12:55 PM EST
11/20/14 - 11:38 AM EST
11/20/14 - 09:55 AM EST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.